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Abstract 
Background:We tested the hypothesis that a single high sensitive troponin at limits of detection 
[LOD](HSTnT)(<5ng/l)combined with a presentation non-ischaemic ECG is superior to low risk 
GRACE(<75),TIMI(≤1) and HEART score(≤3) as an aid to early,safe discharge for suspected ACS(acute 
coronary syndrome) 
Methods:In a prospective cohort study,risk scores were computed in consecutive patients with suspected 
ACS presenting to emergency room (ER) of a large English hospital. Adjudication of MI,as per 3rd 
universal definition,involved 2 physician blinded, independent review of all biomarker positive chest pain 
re-presentations to any national hospital.The primary and secondary outcome was a composite of type 1 
MI, unplanned coronary revascularisation and all cause death[MACE]at 6 weeks and 1 year.  
Results:Of 3054 consecutive presentations with chest pain 1642 had suspected ACS(52% male, median 
age59,14% diabetic,20% previous MI).Median time from chest pain to presentation was 9.7 hours. Re-
presentations occurred in 8 hospitals with 100% follow-up achieved.211(12.9%) and 279(17%) were 
adjudicated to suffer MACE at 6 weeks and 1 year respectively.Only HEART≤3(negative predictive 
value[NPV] MACE 99.4%, sensitivity 97.6%,%discharge 53.4) and LOD HsTnT strategy(NPV MACE 
99.8%,sensitivity 99.5%, %discharge 36.9) achieved pre-specified NPV of >99% for MACE at 6 
weeks.For type 1 MI alone the NPV at 6 weeks and 1 year was identical,for both HEART≤3 and LOD 
HsTnT at 99.8% and 99.5% respectively. 
Conclusion:HEART ≤3 or LOD HSTnT strategy rules out short and medium term MI with ≥99.5% 
certainty,and short-term MACE with > 99% certainty allowing for early discharge of 53.4% and 36.9% 
respectively of suspected ACS. Adoption of either strategy has the potential to greatly reduce ER 
pressures and minimise follow-up investigations. Very early presenters (<3 hours), due to limited 
numbers, are excluded from these conclusions. 
Key words: high sensitivity troponin, acute coronary syndromes. 
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Abbreviations:  
HSTnT= high sensitivity troponin T,  MI= Myocardial Infarction, MACE: major adverse cardiac event 
(composite of type 1 MI, unplanned coronary revascularisation[surgical or PCI) and all cause death,  ER= 
emergency room, CP= chest pain, NPV= negative predictive value. PCI= percutaneous coronary 
intervention, LOD= limits of detection, ACS= acute coronary syndrome 
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Introduction 
Acute CP is one of the commonest presentations to ER in the Western world, the vast majority of which 
are not due to acute MI.1,2,3,4 However early differentiation of type 1 MI from non-cardiac causes of 
troponin elevation remains a challenge despite the emergence of high sensitive troponins.5 Early, safe 
discharge for a substantial proportion of chest pain presentations continues to be the single most 
important challenge, particularly for health care providers. Discharge at presentation with troponin 6 7 at 
the limits of detection  [LOD] or early after a 1-hour high sensitivity troponin strategy remains an 
attractive proposition, 8 9 though there remains concerns about the sensitivity for rule-out of MI in the 1 
hour algorithm particularly for early presenters.9,10 It is not certain if these high sensitive troponin values, 
when combined with clinical assessment, ECG findings and risk factors improve early rule out. A number 
of risk scores which incorporate some or all of these factors have been in existence or been developed 11to 
address this need but to date a high sensitive troponin strategy either alone or combined with risk scores 
as a tool for early discharge has not been tested prospectively in an unselected, consecutive chest pain 
population in whom there is suspicion of an underlying ischaemic cause.    
We compared rule-out strategies; namely a single HSTnT (at limits of detection and at 99th percentile) 
combined with non-ischaemic ECG versus low score HEART (≤3), TIMI (≤1) and GRACE(<75) in an 
unselected consecutive chest pain patient population with suspected ACS. Our goal was to define the 
optimum rule-out strategy for suspected ACS using a single high sensitivity troponin T and presentation 
electrocardiogram. 
 
Methods 
This study was conducted in concordance with STARD criteria for diagnostic studies (score sheet 
included in appendix). From June 2011 to November 2011 all patients presenting to university hospital 
Aintree emergency department with a predominant symptom of chest pain, who had both an 
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electrocardiogram and at least one blood sample for HSTnT check (suspected ACS population), were 
prospectively ‘recruited’ into this study. Aintree university hospital is a large hospital providing 
secondary care cardiology with annual attendances of 80,000 per annum to accident and emergency. Prior 
to the start of the study there was a 3-month ‘roll-in’ phase with conversations between accident and 
emergency clinicians and the development of a chest pain proforma (acute chest pain assessment sheet) 
that highlights important aspects of history taking in chest pain as well as allowing capture of relevant 
information important in computation of the risk scores noted. Use of this proforma was not mandatory 
but was incorporated with casualty sheets as an aide memoire for clinicians for assessment of chest pain. 
Research personnel prospectively and contemporaneously entered demographic, epidemiological data and 
results of blood tests together with timing of ECGs and troponins in a dedicated database. All ECGS were 
stored in an electronic register for subsequent analysis by the research team. Each ECG was read by an 
experienced clinician/ researcher, with a second reading if there was troponin elevation to adjudicate if 
type 1 MI definition had been met. The presence and absence of specific criteria were noted electronically 
in a standardised fashion. The definition of a non-ischaemic ECG was the following: sinus rhythm or 
atrial fibrillation or atrial flutter with ventricular rate<110 together and absence of the following: LBBB, 
paced rhythm, ST segment elevation, ST segment depression, T wave inversion or T wave flattening or 
biphasic T waves in 2 contiguous leads.  For both HSTn T LOD and non-ischaemic ECG strategy and the 
3 risk scores the first(presentation) ECG alone was used as the ECG input variable. Subsequent ECGs 
were extracted for adjudication of MI and to determine possibilities of MI in those with a single sampled 
HSTn T. 
TIMI and GRACE scores were determined from online calculators by research staff with the use of the 
CP proforma, casualty sheets and ambulance proforma alone. To score positively for ST segment 
depression in GRACE and TIMI planar depression of at least 0.5mm after the J-point consistent with the 
Minnesota criteria. 12 
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There was no specific troponin testing protocol for clinicians during recruitment. Guidelines recommended 
repeat troponin sampling for patients who presented <6 hours from chest pain particularly if presentation 
HSTnT was <99th percentile (<15ng/l). Discharge at <6 hours from chest pain with ‘negative’ troponin 
(HSTnT<15ng/l) was discouraged. 
Calculation of HEART score, follow-up, definition and adjudication of MACE events (and 
nonischaemic diagnoses)- see appendix 
High sensitivity cardiac troponin T assay  
The assay used was the high sensitivity troponin T (Roche Elecsys). This has been previously evaluated 
extensively and found to fulfil the definition of high sensitivity with 10% coefficient variation at the 99th 
percentile. 16 Performance of this assay across a number of centres has previously been evaluated. 16 
Analysis was undertaken in-house of COBAS e601 analysers using a standard 18-minute assay. Quality 
control of assay (in-house) at Liverpool Clinical laboratories revealed a coefficient of variation of 11% at 
low value troponins (<10ng/l). External quality assurance provided by the independent United Kingdom 
National External quality assurance scheme (NEQA) revealed inter-hospital coefficient of variation of 
10% (standard deviation 0.5) low level Troponin values. Assay performance (NEQA) was undertaken 
monthly throughout the duration of the study. 
During recruitment of the study there was a downward shift in the ROCHE elecsys HSTn T that was a 
result of calibration of specific LOTS.17   We recomputed HSTnT values by adjusting for the shift by 
reference to local laboratory calibration and that determined by a number of groups including the 
manufacturer. 17,18 The adjusted or recomputed values that were used in the analysis.  
End-points 
The primary endpoint was type 1 MI, unplanned coronary revascularisation and all cause death 
(MACE)at 42 days (see appendix for definitions and adjudication). Unplanned coronary revascularisation 
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was defined as admission for unstable angina or MI necessitating same day or same admission 
coronary revascularisation by percutaneous or surgical means. Secondary endpoint included MACE 
at 1 year 
 
Ethics 
This manuscript conforms to the ICMJE Recommendations for the Conduct, Reporting, Editing, and 
Publication of Scholarly Work in Medical Journals, 
This was an all-comers chest pain study with national(English) hospital involvement for any 
representation with possible MI. The project was registered with the hospital research department and the 
regional ethics board which granted full consent to undertake this study. (north-west England regional 
ethics board) To allow for complete follow-up special permission was granted, in the absence of 
individual consent, via a confidential advisory group(UK government home office appointed) for the 
recruitment of consecutive CP population and collection of data from any hospital nationwide to facilitate 
the retrieval of clinical records and blood results for patients with possible acute coronary syndrome. 
(15/CAG/0171) [http://www.hra.nhs.uk/]  
 
Statistics 
All analyses were performed in Stata v14. 
Summary statistics were presented as n(%) if categorical and as median(IQR) if continuous. For 
categorical variables, a Pearson χ2 test was used to determined p-value, except for cases where there were 
number of MACE events in any category was ≤5, when Fisher’s Exact test was used. For continuous 
variables, a t-test was performed to determine p.  
Confidence intervals for PPV and NPV were calculated using exact binomial proportions. 
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To evaluate differences in NPV in patients who had their first HSTnT at ≤3hrs and ≤6hrs compared to 
those >3hrs and >6hrs, P-values were computed using a 2-sided Fisher’s Exact Test. 
ROC curves were plotted, and area under curve (AUC) computed, using the rocreg function in Stata to 
bootstrap and obtain standard errors and confidence intervals. The p-value for differences in the AUC was 
obtained using a Wald test. 
It was not possible to compute an exact sample size at the time of recruitment as we had no information 
on events rates for HSTnT LOD at the time of starting the study or indeed good evidence of event rates 
for risk scores with high sensitivity troponins.  
 
Results 
Figure 1 charts the global chest pain population and those with suspected ACS(defined as sampling of 
HSTnT together with presentation electrocardiogram). Missing data (loss of casualty cards and 
incomplete/ illegible CP proforma) was <1.2% of the global population. Follow-up was 100% with 
tracking of repeat presentations to ER/ admissions to 8 national hospitals (table 3 appendix). Retrieval of 
all necessary reports, blood results, ECGs, relevant imaging reports, for all patients that had biomarker 
positive presentations was achieved for the purposes of adjudication of MI. 
Table 1 describes the characteristics of all patients (both those admitted and directly discharged from 
accident and emergency department). It further subdivides the population into those adjudicated to have 
suffered type 1 MI and MACE at 6 weeks. 444 patients (27%) were discharged directly from accident and 
emergency at a median of 363 minutes (IQR range 271, 468minutes). Four of these patients suffered 
MACE by 6 weeks (0.9%) (3 were adjudicated to fulfil definition of type 1 MI at index admission [ie 
wrongly discharged]). The decision to admit or discharge was at the discretion of clinicians (at the time 
no specific protocol or risk score was in place to guide clinicians). Those adjudicated to have suffered a 
MACE events (type 1 MI, all cause death, unplanned coronary revascularisation) were older with greater 
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risk factors. Risk scores were consistently higher for all patients with type 1 MI or MACE at 6 weeks 
There were 10.7% of patients adjudicated to have suffered a type 1 MI at index admission with another 
0.3% between admission and 6 weeks at a median of 11 days following admission. The percentage of 
patients undergoing unplanned PCI and unplanned CABG up to 6 weeks were 2.7% and 0.8% 
respectively at a median of 7 and 18 days following admission. The number of patients undergoing 
emergency primary percutaneous coronary intervention for ST elevation myocardial infarction up to 1 
year who were discharged with a diagnosis other than ACS was 4(0.2%) at a median of 80 days following 
discharge. The number of deaths at 6 weeks and 1 year were 25(1.5%) and 104(6.3%) respectively 
occurring at a median of 15 and 112 days respectively. Of the total deaths at 1-year 11% were in-hospital 
and 89% out of hospital. The overall type 1 MI and MACE event rate at 6 weeks was 11.2% and 12.9% 
respectively. For 1 year, the equivalent figures for type 1 MI and MACE were 11.6% and 17%.  For the 
entire population diagnoses other than type 1 MI were the following: type 2 MI 1.2%, unstable angina 
8.5%, atypical chest pain 8.5%, cardiac noncoronary chest pain 7.9%, non-cardiac symptoms 57.2%, CP 
unknown origin 2.8%. (see appendix for prespecified criteria) 
 
Table 2 demonstrates performance of the rule out protocols at 6 weeks and 1 year for MACE and type 1 
MI. Only HEART ≤3 and LOD HSTn T(with non-ischaemic ECG) achieved the prespecified NPV of 
>99% at 6 weeks for MACE (NPV with prespecified 99% performance target represented graphically in 
figure 1 appendix). The discharge potential for these strategies were 53.4% and 36.9% for HEART≤3 and 
LOD HSTn T(with non-ischaemic ECG) respectively. They achieved sensitivities for MACE of 97.6% 
and 99.5% for HEART ≤3 and LOD HSTn T(with nonischaemic ECG) respectively. For Type 1 MI alone 
as an endpoint the respective figures for sensitivity were 98.9% (HEART≤3) and 99.4%(LOD HSTn T 
and nonischaemic ECG). The respective NPV at 6 weeks for type 1 MI for LOD HSTn T and HEART≤3 
was identical at 99.8%. At 1 year point estimates of NPV (99.5%) for type 1 MI was again identical for 
HEART≤3 and HSTnT LOD.  In terms of overlap between LOD HSTn T with nonischaemic ECG and 
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HEART≤3, 521/606 (86.0%) of patients fulfilling discharge rules with LOD  HSTN T + nonischaemic 
ECG also had a HEART score of ≤3. The equivalent percentage for the reverse was 59.4% ie 59.4% with 
HEART score ≤3 had a LOD HSTNT. 
In terms of NPV for MACE events LOD HSTn T and non-ischaemic ECG was clearly differentiated from 
HSTn T ≤14ng/l (99th percentile value)(with nonischaemic ECG) and TIMI ≤1 but not GRACE <75 or 
HEART ≤3. GRACE <75, in terms of discharge potential, could deliver only 28.6% discharges (similar to 
actual direct discharge of 27% in this cohort) 
Table 1 (appendix) details patients with HEART ≤3 and LOD HSTnT and non-ischaemic ECG with 
MACE events (the false negative population or those fulfilling rules for discharge but who had an 
adjudicated MACE). All 3 deaths ≤ 6weeks from index event, that represented 3 of the 5 false negative 
events for patients with HEART ≤3, were clear noncardiac deaths. The performance of HEART≤3 was 
considerably improved by not counting non-cardiac deaths as events. Sensitivity improved to 99% with 
NPV to 99.8% for MACE at 6 weeks. For patients with a first HSTnT LOD (<5ng/L) there were 2 
patients with a 2nd troponin >14ng/l, both of which were adjudicated as suffering type 1 MI(only one of 
which had a non-ischaemic presentation ECG).    
Figure 2 describes ROC(receiver operator characteristic) curves for continuous values of risk scores and 
with HSTnT being analysed without ECG interpretation as a continuous variable.  Compared to 
HSTnT(ROC area 0.918) there was no significant difference in performance with HEART(ROC area 
0.910, p<0.382) but there was significant separation of curves with TIMI(ROC area 0.855, p<0.001) and 
GRACE(ROC area 0.791,p<0.001). Figure 2 (appendix) describes time of chest pain to first HSTnT 
samples.  
 
57% of patients had 1 HSTnT sampled. 51.9% of patients had >1 ECG (median time to first and 2nd ECG 
10mins, [IQR 5,15mins] and  181 mins, [IQR 69,414 mins]). To determine the possibility of missed MI 
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due to single HSTnT<14ng/l we re-evaluated paired ECGs to determine if there were dynamic ECG 
changes(a significant change such as new t wave inversion, ST segment shift, development of LBBB).  in 
those with a single HSTN T Only 3 patients with a single HSTnT had a dynamic change in ECG but in 
only one was a  type 1 MI adjudicated (2nd ECG demonstrated STEMI). His initial ECG though was  not 
normal thus excluding a false negative result for HEART ≤3 and HSTn T LOD (presentation 
HSTnT<5ng/l). 
 
Sensitivity Analysis 
A sensitivity analysis was undertaken with GRACE values of <60 and <90 and TIMI score 0 and ≤2 for 
MACE at 42 days.   
GRACE score <60 did achieve NPV of 99.6% with a sensitivity of 99.5% but percentage discharge 
dropped to 14.3%. GRACE score <90 did not achieve prespecified thresholds of NPV (NPV 97.2%) with 
a sensitivity of 90.5%. TIMI score 0 did achieve threshold NPV of 99.7% with a sensitivity of 99.1% and 
allowed discharge of 39.1% patients. TIMI score ≤2 allowed discharge of 74.1% but at a considerable 
loss of sensitivity and NPV of 73% and 95.3% respectively. 
 
Inter-observer variability of determination or Risk scores 
Absolute agreement for risk scores was were good for HEART and TIMI and excellent (100%) per risk 
category (К=1). No patients were categorised as high or intermediate risk that were initially deemed low 
risk (and vice versa) for HEART and TIMI scores. GRACE scores in terms of absolute agreement 
performed less well but still very good for risk category agreement (К=0.82). (table 4 appendix) 
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Discussion 
We confirm the impressive rule-out strategy of HSTnT using limits of detection (or limit of blank 
alone<3ng/l) 6,7,19 combined with an non-ischaemic ECG. We have prospectively validated the 2 
cornerstones in acute CP assessment, (namely troponins and ECG) as a simple and effective strategy for 
decision making with very low risk of adverse outcome. Rubini-Gimenez et al identified the potential of 
rule-out value of undetectable HSTN T and I. 6 Mokhtari et al further demonstrated incremental value  of 
the combination of  HSTn T LOD, nonischaemic ECG and low risk history but in a non-consecutive 
patient series.20   As far as we are aware this is the only study that has prospectively assessed  HSTn T at 
LOD and non-ischaemic EC) in an unselected, consecutive chest patient population. Our point estimate 
of NPV are similar to that of Bandstein et al7 and Body et al 19 even though a lower limit of blank 
(<3ng/l) was used in the latter study.Sandoval et al define the concept of LOD and LOB as rule out 
strategies. 21 The LOD provide higher NPV and sensitivities than that of Rubini-Gimenez et al.6 
Incorporation of a non-ischaemic ECG to the limits of detection of HSTnT could explain this; LOD 
HSTnT together with nonischaemic ECG increased sensitivity from 98.1% to 99.5% for MACE and 
98.9% to 99.4% for type 1 MI at 6 weeks (table 2).   
This study is the first to demonstrate that HEART score≤3 in the era of high sensitive troponins (using 
conventional cut-offs of HSTnT) also, to a large extent, meets criteria for a rule-out strategy. HEART≤3 
was as effective as LOD HSTn T with a non-ischaemic ECG) for rule-out of type 1 MI at 6 weeks with 
NPV of 99.8% with a sensitivity of 98.9% allowing a discharge of 53.4% of patients(as opposed to 36.9% 
of patients with LOD HSTnT strategy). The performance of HEART ≤3 for type 1 MI is indicative of an 
acceptable risk for a discharge/ rule out for type 1 MI. 22In terms of MACE sensitivity was <98% but 
improved to 99% (at 6 weeks if only cardiac deaths were counted)  
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In addition this study have demonstrated that both rule-out strategies (HEART ≤3 and LOD HSTnT) have 
low event rates to 1 year for type 1 MI(99.5% at 1 year) indicating patients can be safely discharged and 
reassured without the need for early diagnostic testing in the absence of ongoing symptoms. This study 
suggests cardiac imaging for LOD HSTNT or low risk HEART score cannot seek to refine risk further 
and argues for a reduction to these requests in low risk patients. 
TIMI score≤1 and GRACE score<75 did not reach prespecified thresholds for rule-out. Although neither 
of these risk scores had been originally validated for suspected ACS, they have been evaluated with 
encouraging results in combination with high sensitive troponins in a number of different protocols in 
chest pain populations. 232425 Sensitivity analysis revealed that TIMI score of 0 had acceptable 
performance but discharged considerably less than HEART≤3. (39.5%vs 53.4%) 
A consecutive, unselected series of suspected ACS presentation, in a sample size this large, is important 
in terms of generalisability and therefore potential influence to change practise (as opposed to a selected 
population, a natural consequence of consent and limited or absent recruitment nocturnally or at 
weekends). There was 100% follow-up tracked nationally and there was adjudication of any index CP or 
representation with HSTn T that was above the 99th percentile. This allowed us not only to validate those 
coded for type 1 MI but to evaluate all patients with elevated troponins including those who were deemed 
to have noncardiac pathologies (a distinction from other noted studies). 7 Secondly we used all-cause 
death as an outcome rather than cardiac death as incorporated in some studies.3This is not to say that high 
sensitivity troponin can predict noncardiac death but to accept the uncertainty of cause of death, 
particularly for out of hospital deaths and the probability of misdiagnosis and therefore miscoding of 
cause of death. 26Using all-cause death grants a safer estimate of rule-out protocols. 
Recently Carlton et al directly compared risk scores using HSTn T and I in a select patient population of 
patients ≤80 years of age.27 In a post-hoc analysis HEART ≤3 did not achieve pre-specified targets of 
>99.5% NPV and/or sensitivity of >98% with either HSTn T or HSTn I. Differences in study population 
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could explain this; Carlton et al had a population with much shorter time of CP to presentation which is 
likely to have reduced both NPV and sensitivity for HEART≤3.  
The largest study to date in a population of all-comers similar to ours was that by Shah et al.3 The 
impressive NPV of 99.6% (high sensitive troponin I- Abbot) with both a derivation and validation cohort 
fulfilled criteria for safety and clinical utility (almost 2/3rd could be discharged). However, there was no 
reported sensitivity as far as our group could discern. NPV is affected by disease prevalence rates thus 
highlighting the attractiveness of risk scores such as HEART which to some extent incorporate this aspect 
allowing potential widespread applicability of rule-out strategies for suspected ACS. Multicentre 
validation studies, preferably with studies enriched with early presenters, and with competitor high 
sensitivity troponin assays incorporated in HEART are important to confirm (or refute) the potential of 
the HEART score as a tool for rule-out of ACS.  
 
In a previous study by Backus et al investigating the same risk scores in 2338 suspected ACS in a 
multicentre observational study revealed superiority of HEART compared to TIMI and GRACE across all 
risk categories but there was a 1.7% MACE event at 6 weeks with HEART≤3 with 4th generation (non-
high sensitivity) troponins. This event rate would not be acceptable strategy as a rule-out in most health 
care systems.3 High sensitivity troponins are likely to have improved sensitivity or rule-out value at the 
expense of reduced specificity. 
Limitations 
Figure 2 (appendix) demonstrates time from chest pain to first HsTn T check.Only 4.4% of patients had a 
HSTn T check <3 hours (very early presenters) from chest pain.The equivalent number for ≤6 hours was 
240 (14.6%).There was no significant difference in NPV between those with ≤6 hours and the global 
population when incorporated in a troponin and ECG strategy or as low risk scores. (table 5 appendix). 
However these results should be treated with caution due to the low number of events occurring in 
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patients presenting early.  Most CP presentations to ER are late, and the study does represent comparable 
numbers of patients with very early (≤3hours)3 and early presentations (≤6hours)7 to similar ‘all-comer’ 
studies. This study does not validate discharge for very early presenters, based on a single HSTnT. 
43% patients underwent serial troponins. As a rise or fall in troponins or biomarkers of myocyte necrosis 
is part of the universal definition of MI we cannot be certain that MIs were not missed although most 
presentations are late (median time from CP to presentation 9.6 hours) thus reducing the possibility of a 
later rise of HSTn T beyond 99th percentile. Furthermore analysis of paired ECGS, in those with a single 
HSTnT sampled,for sequential ECG changes only revealed one definite MI (evolving ECG changes from 
t wave inversion to STEV).  
There was a downward shift seen with this ROCHE assay between 2010 and 2012. 28 The actual 
difference computed between affected lots and correct (re-assayed) values was 1.2ng/l in a similar 
population of suspected acute coronary syndrome.18 Wildi et al suggested a small miss rate with LOD 
HSTnT in affected lots compared to corrected values with serial samples and re-adjudication for MI. 
However 2 other analyses suggest similar prevalence rates of MI and no ‘missed’ MI with LOD initial 
samples when ECG ischaemia was taken into account. 29 Body et al using LOD revealed 2 missed MIs 
using paired samples in 463 patients with affected lots with retesting, but both patients had ischaemic 
ECGS maintaining NPV at 100%. In addition ROCHE internally  assessed the effect of affected lots with 
readjustment mathematically in 1033 patients presenting to ER.28 The identical number of MIs were 
defined. 
 
Finally HEART score was not determined by attending physicians but researchers following presentation 
raising concerns about scoring chest pain section of HEART. However due both to engagement and the 
production of a tick box chest pain proforma that emphasises character and duration of CP it was always 
possible to score chest pain with reasonable reflection of clinician suspicion. 
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Conclusion 
Heart ≤3 and LOD HSTnT (combined with a non-ischaemic ECG) are optimum rule-out strategies for 
MACE at 6 weeks, for a suspected ACS population. Further multicentre studies should test HEART ≤3 as a 
tool for early, safe discharge of patients with chest pain and suspected ACS particularly in early presenters. A 
randomised trial of LOD HSTnT versus a 1 hour HS troponin protocol decision rule to assess duration of stay and 
safety endpoints is urgently needed. 
Role of the funder: The funder played no role in the design, execution nor had they any part in the 
writing up of the study. Aintree innovation awards (Dragons den) undertakes to award via competitive 
bids innovative works that have the potential to improve health care delivery. The trust board and 
executive do not oversee research or innovative work. 
Disclosures:  Dr Aleem Khand has the following potential conflicts of interest: free of charge material 
from ROCHE for research. Submissions pending for research funds from ROCHE and Abbott. Funding 
for national conferences from Daiichi Sankyo, Bayer. Funding for research from Bayer pharmaceuticals. 
Speaker and expert consultation fees from Astra Zeneca, Menarini,Bayer. No other authors report 
potential conflict of interest. 
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Figure Legends 
 
Figure 1: Flowchart of final population 
 
Figures 2: ROC (receiver operator characteristics) curve for primary outcome (MACE) at 6 weeks 
 
Appendix figures 
Figure 1: Negative and Positive predictive values for MACE (type 1 myocardial infarction, unplanned 
coronary revascularisation and all cause death) at 42 days according to rule-out protocols 
Figure 2: Time of chest pain to first High sensitivity troponin check 
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Table 1 Population characteristics 
 All Type 1 MI (6 weeks) MACE (6 weeks) P value 
Totals 1642 180 211  
Age (median[IQR]) 59(47,72) 74(62,82) 74(62,82) <0.001 
 N N N  
Sex: (Male) 858(52%) 109 (61%) 127(60%) 0.015 
Risk Scores TIMI (MEAN, sd) 1.50 (1.58) 3.47 (1.36) 3.38 (1.38) NA 
 HEART (mean, sd) 3.50 (2.30) 6.93 (1.61) 6.72 (1.71) 
 GRACE (mean, sd) 101.5 (39.6) 136.4 (32.1) 136.7 (35.7) 
Hypertension 695(42%) 121 (67%) 140 (66%) <0.001 
Smoking* Current 457(28%) 42 (23%) 50 (24%) 0.005 
 Previous 463(28%) 68 (38%) 82 (39%) 
 Never 589(36%) 59 (33%) 66 (31%) 
Diabetes mellitus 237(14%) 44 (24%) 55 (26%) <0.001 
Dyslipidaemia 432(26%) 75 (42%) 82 (39%) <0.001 
Family History of premature CAD^ 337(21%) 34 (19%) 37 (18%) 0.302 
Previous MI 322(20%) 65 (36%) 72(34%) <0.001 
Previous PCI 170 (10%) 32 (18%) 36 (17%) 0.001 
Previous CABG 91 (6%) 21 (12%) 22 (10%) 0.001 
Previous stroke 118(7%) 22 (12%) 29 (14%) <0.001 
History of AF 164(10%) 29 (17%) 36 (17%) <0.001 
Hb (median(IQR)) g/dl 13.7(12.5,14.8) 13.0(11.7,14.4) 12.9(11.7,14.3) 0.023 
MCV (median (IQR)) femtolitres 88.7(85.6,92.0) 89.6(86.1,92.7) 89.3(85.5,92.5) 0.780 
Creatinine [median, IQR) mmol/l 91(79,105) 98(86,116) 97(84,118) <0.001 
C- reactive protein (median, IQR) mg/dl 4(4,9) 4(4,10) 4(4,13) 0.03 
Systolic BP (median(IQR)) mmHg 131(118,146) 139(122,152) 136(121.151) 0.001 
Heart Rate (median, IQR) {beats/min} 78(67,90) 77(66,88) 77(66,90) 0.89 
CP onset/peak to presentation (median, IQR) hours 9.7(2.4,48.0) 4.2(1.6,15.7) 4.6(1.7,18.6) <0.001 
Time of chest pain+ to presentation    <0.001 
 <6hrs 682(42%) 98 (56%) 111 (55%) 
 ≥6hrs 946(58%) 73 (42%) 90 (43%) 
CP onset/peak to first troponin check (median, IQR) 
hours 
14.0(6.8,49.0) 8.6(6.2,18.7) 9.2(6.2,21.0) <0.001 
Time of peak CP to first troponin    0.001 
 ≤6hrs 240(15%) 40 (22%) 47 (22%) 
 >6hrs 1389(85%) 136 (75%) 159 (75%) 
ECG Ischaemic∞ 463(28%) 107 (59%) 123 (58%) <0.001 
ST depression ≥0.5mms 90(5%) 33 (20%) 37 (18%) <0.001 
T wave pathology    <0.001 
 Nil 1262(77%) 93 (52%) 113 (54%) 
 Flat 73(4%) 12 (7%) 13 (6%) 
 Biphasic 31(2%) 11 (6%) 14 (7%) 
 Inverted 274(17%) 64 (36%) 71 (34%) 
Current aspirin use 491(30%) 86 (48%) 99 (47%) <0.001 
*Ie not known smoking status in 8%, ^ not known in 32%, + timing of chest pain uncertain in 1%, ∞ ischaemic ECG was defined as the 
following: rhythm other than sinus rhythm or AF/flutter with heart rate >110bpm, LBBB, paced rhythm, ST segment elevation, ST segment 
depression, T wave inversion or T wave flattening or biphasic T waves in 2 contiguous leads 
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Table 2: Performance of rule-out protocols for type 1 myocardial infarction and MACE at 6 weeks and 1 year 
Abbreviations: MACE= major adverse cardiac event, NPV= negative predictive value, PPV= positive predictive value. HSTnT= high sensitivity troponin T 
MACE (type 1 Myocardial Infarction, unplanned coronary revascularisation and all cause death) 
Rule-out 
protocol 
Discharge 
potential(%) 
6 weeks 1 year 
PPV (95% CI) NPV (95% CI) Sensitivity (95%CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Sensitivity (95%CI) Specificity (95% CI) 
TIMI ≤ 1 56.7 0.270  
(0.238, 0.304) 
0.980 
 (0.968, 0.988) 
0.910 
(0.863,0.945) 
0.637 
(0.612,0.662) 
0.339 
(0.304,0.375) 
0.959 
(0.944,0.971) 
0.864 
(0.818,0.902) 
0.655 
(0.629,0.680) 
GRACE <75 28.6 0.172  
(0.151, 0.195) 
0.981  
(0.964, 0.991) 
0.957(0.921, 
0.980) 
0.322 
(0.298,0.347) 
0.229 
(0.205,0.254) 
0.977 
(0.958,0.988) 
0.961 
(0.931,0.980) 
0.336 
(0.311,0.362) 
HEART ≤ 3 53.4 0.269  
(0.238, 0.302) 
0.994  
(0.987, 0.998) 
0.976 
(0.946,0.992) 
0.609 
(0.584,0.635) 
0.331 
(0.297,0.365) 
0.970 
(0.957,0.981) 
0.907 
(0.866,0.938) 
0.624 
(0.598,0.650) 
HSTnT<5ng/l, ECG 
non-ischaemic 
36.9 0.203  
(0.179, 0.228) 
0.998  
(0.991, 1.000) 
0.995 
(0.974,1.000) 
0.423 
(0.397,0.449) 
0.259 
(0.232,0.286) 
0.982 
(0.968,0.991) 
0.961  
(0.931,0.980) 
0.437 
(0.410,0.463) 
HSTnT<15ng/l, ECG 
non-ischaemic 
59.4 0.291  
(0.257, 0.327) 
0.983  
(0.972, 0.990) 
0.919 
(0.874,0.952) 
0.669 
(0.644,0.694) 
0.360 
(0.323,0.398) 
0.960 
(0.946,0.971) 
0.860 
(0.814,0.899) 
0.687 
(0.661,0.711) 
HSTnT<5 ng/l alone 43.3 0.222  
(0.196, 0.250) 
0.994  
(0.986, 0.998) 
0.981 
(0.952,0.995) 
0.494 
(0.468,0.520) 
0.282 (0.254, 
0.313) 
0.977 (0.964, 
0.987) 
0.943 
(0.909,0.967) 
0.510 
(0.483,0.537) 
Type 1 Myocardial infarction 
Rule-out 
protocol 
Discharge 
potential(%) 
   6 weeks 1 year 
PPV (95% CI) NPV (95% CI) Sensitivity(95%CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Sensitivity (95%CI) Specificity (95% CI) 
TIMI ≤ 1 56.7 0.232  
(0.201, 0.265) 
0.984  
(0.974, 0.991) 
0.917 
(0.866,0.953) 
0.627 
(0.601,0.651) 
0.245  
(0.214, 0.278) 
0.982  
(0.971, 0.989) 
0.911 
(0.861,0.947) 
0.630 
(0.604,0.655) 
GRACE <75 28.6 0.149  
(0.129, 0.171) 
0.989  
(0.975, 0.997) 
0.972 
(0.936,0.991) 
0.318 
(0.294,0.342) 
0.158  
(0.137, 0.180) 
0.987 
(0.972, 0.995) 
0.969 
(0.933,0.988) 
0.319 
(0.295,0.344) 
HEART ≤ 3 53.4 0.233  
(0.203, 0.264) 
0.998  
(0.992, 1.000) 
0.989 
(0.960,0.999) 
0.598 
(0.573,0.624) 
0.244  
(0.214, 0.277) 
0.995  
(0.988, 0.999) 
0.979 
(0.947,0.994) 
0.602 
(0.576,0.627) 
HSTnT<5ng/l, ECG 
non-ischaemic 
36.9 0.173  
(0.150, 0.197) 
0.998  
(0.991, 1.000) 
0.994 
(0.969,1.000) 
0.414 
(0.388,0.440) 
0.181 
(0.158,0.206) 
0.995  
(0.986, 0.999) 
0.984 
(0.955,0.997) 
0.416 
(0.390,0.441) 
HSTnT<15ng/l, ECG 
non-ischaemic 
59.4 0.250  
(0.218, 0.285) 
0.987  
(0.977, 0.993) 
0.928 
(0.880,0.961) 
0.658 
(0.633,0.682) 
0.261  
(0.228, 0.296) 
0.983  
(0.972, 0.990) 
0.911 
(0.861,0.947) 
0.660 
(0.635,0.685) 
HSTnT<5ng/l alone  43.3 0.191  
(0.166, 0.218) 
0.997  
(0.990, 1.000) 
0.989 
(0.960,0.999) 
0.485 
(0.459,0.511) 
0.201  
(0.176, 0.228) 
0.994  
(0.986, 0.998) 
0.979 
(0.947,0.994) 
0.487 
(0.461,0.513) 
Figure 1: Flowchart of final population 
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Missing notes, ECG 
48 
 
Trop Haemolysed 
9 
<18 years of age 
7 
 
1785 
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*MACE= 211 
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indicate total number of events in each category, not 
individual patients with MACE  
Figure 2: ROC (receiver operator characteristics) curve for primary outcome (MACE) at 6 weeks 
ROC curves for risk scores (continuous) and high sensitive troponin T (HsTn T is a continuous variable without ECG criteria)
 
 
 
Area under curve: HSTnT 0.918, HEART 0.910, TIMI 0.855 [p<0.001 cf to HSTnT], GRACE 0.791[p<0.001 cf to HSTnT] 
A direct comparison of decision rules for early discharge of suspected acute 
coronary syndromes in the era of high sensitive troponin 
Chew P, Khand A et al 
Calculation of the HEART score 
The character of CP was scored exclusively on the narrative in the admission documentation 
and/or chest pain proforma. A score of 2 was ascribed when chest pain had documented 
features suggestive of cardiac chest pain and an absence of non-specific features. A score of 1 
was given if there was combination of suspicious and non-specific symptoms and a score of 0 
was given if there were only non-specific features. Researchers were prompted to grant high 
suspicion (a score of 2) if there was central chest pain with at least one additional feature 
such as radiation to the arm/ neck/jaw or sweating or relief with GTN or provocation of chest 
pain with exertion or emotion/stress. Admission ECGs were reviewed and ascribed a score of 
2 in the presence of ST depression ≥0.5mm and 1 in the presence of bifid or inverted T waves 
or flat T waves in at least 2 contiguous leads of a 12 lead ECG. LBBB and paced rhythm 
were given a score of 1. Age categories were as per the HEART score. Risk factors 
considered were hypertension, smoking (current or ex-smoker <1 year), diabetes mellitus, 
hypercholesterolemia, positive family history and previous history of confirmed 
atherosclerotic coronary (this latter group included previous MI, CABG, percutaneous 
coronary intervention, cerebrovascular disease and stroke). We did not have consistent 
information on body weight and therefore were unable to score BMI>30 as a risk factor in 
HEART. The presence of ≥3, 1-2 and 0 risk factors for coronary artery disease scored 2,1 and 
0 respectively (Confirmed atherosclerotic disease was attributed a score of 2 even in the 
absence of other risk factors).. A score of 0 was ascribed with HSTnT values of<15ng/l,  
values between 15 and 41ng/l a score of 1 was given and 2 for values  >42. This is consistent 
with HEART with scores dependant on 99th percentile of troponins in the reference 
population (0≤99th percentile, 1 for 99th percentile to 3X 99th percentile and a score of 2 for 
>x3 99th percentile).11  
To ascertain inter-observer variability of risk score determination 2 researchers (AK and FF) 
undertook blinded assessment and repeat computation of risk scores of a random selection of 
18 presentations with suspected ACS. 
Follow-up 
All clinicians were blinded to outcome of patients (except for inpatient death or death during 
subsequent admission). However, they could be aware of presentation troponins. 
Patients were tracked by a linked national database by their NHS number (these are 16 digit 
codes and act as unique identifiers to any hospital in England). Codes for readmission were 
for any chest pain code or any code for ischaemic heart disease or for any coronary 
revascularisation (PCI or CABG) – see appendix (table 2 for list of codes). Deaths were 
tracked via the national mortality database. There were 30 patients without NHS numbers. 
For these patients to ascertain outcome we systematically contacted their general practitioners 
and the records department of 5 hospitals in the Cheshire and Mersey region (comprising a 
catchment population of 2.1million). All analyses for outcomes were independently 
undertaken by the statistician with outcomes spreadsheet and index presentation/ risk scores 
linked by a unique patient identifier only. 
 
Adjudication of type 1 myocardial infarction/ MACE 
For all index presentations 2 research clinicians independently reviewed all cases where at 
least one HSTn T was above 99th percentile (ie 14ng/l).  All investigations including serial 
ECGS, echocardiograms, other imaging investigations and angiograms up to 6 weeks from 
index admission were scrutinised to determine if a definition of type 1 or 2 MI was met. For 
index admission 2nd adjudicator was not blinded to the adjudication/ diagnosis of the first  
(unblinded). Disagreements were resolved by adjudication by a consultant cardiologist 
experienced in endpoint definition in clinical studies. For all possible re-infarctions (patients 
who had a further episode of chest pain with repeat HSTnT sampling outwith the initial 
sampling period) following presentation and representations with chest pain to any English 
hospital (appendix table 3 appendix) up to 1 year from discharge were selected (table 2 for 
ICD 10 codes used). The presence or absence of biomarker elevation (according to local 
laboratory reference range) was determined. In case of biomarker elevation independent and 
blinded (to index event and risk scores) adjudication was undertaken by 2 experienced 
clinicians (with a 3rd involved for divergences in adjudication). The criteria for defining MI, 
for both index admission events and readmissions, was based on the 3rd universal definition 
for MI. 13Adjudicators were recommended that 50% rise or fall in a 2nd troponin was 
confirmatory of MI but 20-50% rise or fall was suggestive particularly in the context of 
convincing ischaemic symptoms or other corroborating evidence.  
Type 2 MI was defined as evidence of myocardial ischaemia with myocyte necrosis but 
associated with an imbalance in supply and demand such as tachydysrhythmia, profound 
anaemia, hypotension. Agreement between clinicians for the presence or absence of 
myocardial infarction (repeat presentation with biomarker elevation) was 85%, К=0.58.  
For patients who had multiple repeat presentations with chest pain the first presentation was 
assessed for biomarker elevation and/ or adjudication for type 1 MI. If type 1 MI was 
confirmed, then subsequent admissions/ presentations were censored. If the first readmission 
was negative for type 1 MI or biomarker evaluation, then subsequent presentations with 
biomarker positive chest pain was adjudicated until a MACE (Major Adverse cardiac event) 
was defined or presentations were exhausted. It is important to note that nationally not all 
hospitals utilised high sensitivity troponins. (table 3 appendix details all hospital with 
troponins used [for adjudication] with representation with a possible MI). 
We did not apply sex specific cut-offs to HSTnT. This was not the practise in our institute 
and recent evidence suggests limited value and consequence to this approach using this HSTn 
T assay.14 
For all coronary revascularisations (surgical or percutaneous) a single consultant cardiologist 
adjudicated (by reference to discharge letters, review of coronary angiograms, biochemistry, 
biomarkers status) if an attempt at revascularisation (coronary artery bypass surgery or 
percutaneous coronary artery intervention) did occur and if so whether it fulfilled criteria for 
unplanned coronary revascularisation. (defined as hospital admission with unstable angina/ 
acute coronary syndrome, deemed to require inpatient revascularisation inclusive of primary 
percutaneous coronary interventions). As a case ascertainment exercise all national codes for 
coronary revascularisation were compared to in-house linkage for any revascularisation at the 
local tertiary centre for revascularisation. An additional 2 cases of urgent/ emergency 
revascularisation were identified   by this exercise (that had been miscoded as non-coronary 
surgical intervention).  Contentious outcomes based on coronary revascularisation underwent 
adjudication by an endpoint committee. (AK, PC, LM, FF) 
Non-MI adjudication in index admission 
Researchers were asked separately to diagnose non-MI diagnoses using all available 
information at index admission. The criteria for agreed and prespecified (drop-down) field 
settings. 
Unstable Angina: Patients with normal cardiac troponin levels and typical angina at rest, a 
deterioration of a previously stable angina and in cases of positive cardiac exercise testing or cardiac 
catheterization with coronary arteries found to have a stenosis of 70% or greater. 
Atypical Chest Pain: 2/3 features fulfilled for NICE criteria of ischaemic chest pain 15 
Cardiac Non-Coronary Chest pain: Convincing cardiac pathology with evidence for non-coronary 
disease; eg pericarditis, myocarditis, arrhythmia related 
Non-cardiac Chest Pain: musculoskeletal pain, gastroesophageal disorder, pulmonary embolism or 
other causes of noncardiac chest pain 
Chest pain of unknown origin: If diagnosis remained uncertain or insufficient diagnostic 
procedures/tests were performed 
 
Appendix: supplementary tables and figures 
Table 1: Patients with False negative HEART ≤3 and HSTnT limit of Detection at 6 weeks – details of presentation and major adverse cardiac 
events 
Age Gender HEART 
score 
Heart score 
criteria 
Presentation 
ECG 
HstnT 
1 
HStnT 
2 
Timing of 
HSTN T: CP to 
HS tn T 
Cause of death Additional descriptor ICD code MACE 
Event 
False Negative HEART score ≤3 
61 male 3 Age (1), RF: 
smoking (1), 
moderately 
suspicious CP (1) 
SR, non-
ischaemic 
6  40hr 25 mins N/A Readmission with MI 
(Hstn T 87, 117) 
16 days following 
discharge 
R073 (pain 
in chest 
wall) 
Subseq-
uent MI 
93 female 3 Age (2), hstn T (1) SR, 1st degree 
HB, non-
ischaemic 
19 33 5hr 8 mins N/A Index MI (3rd adjudicator 
involved) 
R073 Index MI 
51 male 3 Pvd (2), age (1) Sinus rhythm, 
non-ischaemia 
8  16hrs 30 mins 1. Gastrointestinal 
bleed secondary 
alcohol excess 2. Acute 
liver failure  
Clear non-cardiac cause - 
index admission death 
K720 (acute 
hepatic 
failure) 
Non-
cardiac 
Death  
55 female 2 Age (1), 
hypertension (1) 
SR, non- 
ischaemic 
9 2 1hr 18 mins Lung adenocarcinoma 
with bony metastases 
Clear non-cardiac cause, 
index admission death 
C349,M8250
/3 
Non-
cardiac 
Death 
69 male 3 Age (2), RFs: 
smoking, 
hypertension (1) 
SR, non-
ischaemic 
10  50hr 45 minutes Small cell carcinoma of 
lung 
Died at home 3 days 
after discharge 
C349 
M8041/3 
Non-
cardiac 
Death 
False negative high sensitivity troponin T (LOD) and non-ischaemic ECG 
65 male 4 Age (2),risk factors 
(1), moderately 
suspicious CP (1) 
SR, non-
ischaemic 
3 18 314minutes N/A Index MI RO72 
(central 
chest pain 
Index MI 
Abbreviations: SR= sinus rhythm, Hstn T= high sensitivity troponin T, ECG= electrocardiogram, MI= myocardial Infarction, PVD= peripheral vascular disease, ICD = international classification of disease, CP= Chest 
pain, N/A = not applicable, LOD= limit of detection 
Table 2a: ICD 10 Revascularisation codes used 
CLINICAL_CODE CODE_SET_ID VERSION SHORT_DESC LONG_DESC OPCS_VERSION 
K40 OPCS 4 
SAPHENOUS VEIN GRAFT 
REPLACEME SAPHENOUS VEIN GRAFT REPLACEMENT OF CORONARY ARTERY 4.2 
K401 OPCS 4 Saphenous vein graft replaceme Saphenous vein graft replacement of one coronary artery 4.2 
K4010 OPCS 4 Coronary Artery Bypass Grafts SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS  SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B11 OPCS 4 Coronary Artery Bypass Grafts SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B14 OPCS 4 CORONARY BYPASS GRAFTS - ENDO  SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B16 OPCS 4 REPAIR ASC. AORTA & COR. BYPAS SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B17 OPCS 4 REPAIR AORTIC ANEURYSM & BYPAS SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B18 OPCS 4 CABG & OTHER MAJOR CARDIAC (EG SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B1A OPCS 4 TMR & CABG SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B1B OPCS 4 
CABG & CAROTID 
ENDARTERECTOMY SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B1C OPCS 4 
CABG & ABDOMINAL AORTIC 
ANEURY SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B21 OPCS 4 REPLACEMENT/REPAIR OF VALVE(S) SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B22 OPCS 4 Coronary Artery Bypass Grafts SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K4010B23 OPCS 4 COMPOSITE REPL AORTA,VALVE + C SAPHENOUS VEIN GRAFT REPLACEMENT OF ONE CORONARY ARTERY 4.2 
K402 OPCS 4 Saphenous vein graft replaceme Saphenous vein graft replacement of two coronary arteries 4.2 
K4020 OPCS 4 Coronary Artery Bypass Grafts 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS  
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B11 OPCS 4 Coronary Artery Bypass Grafts 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B14 OPCS 4 CORONARY BYPASS GRAFTS - ENDO  
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B16 OPCS 4 REPAIR ASC. AORTA & COR. BYPAS 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B17 OPCS 4 REPAIR AORTIC ANEURYSM & BYPAS 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B18 OPCS 4 CABG & OTHER MAJOR CARDIAC (EG 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B1A OPCS 4 TMR & CABG 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B1B OPCS 4 
CABG & CAROTID 
ENDARTERECTOMY 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B1C OPCS 4 
CABG & ABDOMINAL AORTIC 
ANEURY 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B21 OPCS 4 REPLACEMENT/REPAIR OF VALVE(S) 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B22 OPCS 4 CABG + AVR + Carotid Endartere 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B23 OPCS 4 COMPOSITE REPL AORTA,VALVE + C 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K4020B32 OPCS 4 Coronary Artery Bypass Grafts 
SAPHENOUS VEIN GRAFT REPLACEMENT OF TWO CORONARY 
ARTERIES 4.2 
K403 OPCS 4 Saphenous vein graft replaceme Saphenous vein graft replacement of three coronary arteries 4.2 
K4030 OPCS 4 Coronary Artery Bypass Grafts 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS  
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B11 OPCS 4 Coronary Artery Bypass Grafts 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B14 OPCS 4 CORONARY BYPASS GRAFTS - ENDO  
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B16 OPCS 4 REPAIR ASC. AORTA & COR. BYPAS 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B18 OPCS 4 CABG & OTHER MAJOR CARDIAC (EG 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B1A OPCS 4 TMR & CABG 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B1B OPCS 4 
CABG & CAROTID 
ENDARTERECTOMY 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B1C OPCS 4 
CABG & ABDOMINAL AORTIC 
ANEURY 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B21 OPCS 4 REPLACEMENT/REPAIR OF VALVE(S) 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B22 OPCS 4 CABG + AVR + Carotid Endartere 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B23 OPCS 4 COMPOSITE REPL AORTA,VALVE + C 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K4030B42 OPCS 4 Coronary Artery Bypass Grafts 
SAPHENOUS VEIN GRAFT REPLACEMENT OF THREE CORONARY 
ARTERIES 4.2 
K404 OPCS 4 Saphenous vein graft replaceme Saphenous vein graft replacement of four or more coronary ar 4.2 
K4040 OPCS 4 Coronary Artery Bypass Grafts 
SAPHENOUS VEIN GRAFT REPLACEMENT OF FOUR OR MORE 
CORONARY AR 4.2 
K4040B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B11 OPCS 4 CORONARY ARTERY BYPASS GRAFTS 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B14 OPCS 4 CORONARY BYPASS GRAFTS - ENDO 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B16 OPCS 4 REPAIR ASC. AORTA & COR. BYPAS 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B18 OPCS 4 CABG & OTHER MAJOR CARDIAC (EG 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B1A OPCS 4 TMR & CABG 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B1B OPCS 4 
CABG & CAROTID 
ENDARTERECTOMY 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B21 OPCS 4 REPLACEMENT/REPAIR OF VALVE(S) 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B22 OPCS 4 CABG + AVR + CAROTID ENDARTERE 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B23 OPCS 4 COMPOSITE REPL AORTA,VALVE + C 
SAPHENOUS VEIN GRAFT REPLACE FOUR OR MORE CORONARY 
ARTERIES 4.2 
K4040B52 OPCS 4 Coronary Artery Bypass Grafts 
SAPHENOUS VEIN GRAFT REPLACEMENT OF FOUR OR MORE 
CORONARY AR 4.2 
K408 OPCS 4 Other specified saphenous vein Other specified saphenous vein graft replacement of coronary 4.2 
K409 OPCS 4 Unspecified saphenous vein gra Unspecified saphenous vein graft replacement of coronary art 4.2 
K41 OPCS 4 
OTHER AUTOGRAFT REPLACEMENT 
OF OTHER AUTOGRAFT REPLACEMENT OF CORONARY ARTERY 4.2 
K411 OPCS 4 Autograft replacement of one c Autograft replacement of one coronary artery NEC 4.2 
K4110 OPCS 4 CABG + AVR + Carotid Endartere AUTOGRAFT REPLACEMENT OF ONE CORONARY ARTERY NEC 4.2 
K4110B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS  AUTOGRAFT REPLACEMENT OF ONE CORONARY ARTERY NEC 4.2 
K4110B11 OPCS 4 Coronary Artery Bypass Grafts AUTOGRAFT REPLACEMENT OF ONE CORONARY ARTERY NEC 4.2 
K4110B1A OPCS 4 TMR & CABG AUTOGRAFT REPLACEMENT OF ONE CORONARY ARTERY NEC 4.2 
K4110B21 OPCS 4 AUTO REPLACE ONE CON ART AUTOGRAFT REPLACEMENT OF ONE CORONARY ARTERY NEC 4.2 
K4110B22 OPCS 4 CABG + AVR + Carotid Endartere AUTOGRAFT REPLACEMENT OF ONE CORONARY ARTERY NEC 4.2 
K412 OPCS 4 Autograft replacement of two c Autograft replacement of two coronary arteries NEC 4.2 
K4120 OPCS 4 CABG + AVR + Carotid Endartere AUTOGRAFT REPLACEMENT OF TWO CORONARY ARTERIES NEC 4.2 
K4120B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS  AUTOGRAFT REPLACEMENT OF TWO CORONARY ARTERIES NEC 4.2 
K4120B11 OPCS 4 Coronary Artery Bypass Grafts AUTOGRAFT REPLACEMENT OF TWO CORONARY ARTERIES NEC 4.2 
K4120B1A OPCS 4 TMR & CABG AUTOGRAFT REPLACEMENT OF TWO CORONARY ARTERIES NEC 4.2 
K4120B21 OPCS 4 AUTO REPLACE TWO CON ART AUTOGRAFT REPLACEMENT OF TWO CORONARY ARTERIES NEC 4.2 
K4120B22 OPCS 4 CABG + AVR + Carotid Endartere AUTOGRAFT REPLACEMENT OF TWO CORONARY ARTERIES NEC 4.2 
K413 OPCS 4 Autograft replacement of three Autograft replacement of three coronary arteries NEC 4.2 
K4130 OPCS 4 CABG + AVR + Carotid Endartere AUTOGRAFT REPLACEMENT OF THREE CORONARY ARTERIES NEC 4.2 
K4130B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS  AUTOGRAFT REPLACEMENT OF THREE CORONARY ARTERIES NEC 4.2 
K4130B11 OPCS 4 Coronary Artery Bypass Grafts AUTOGRAFT REPLACEMENT OF THREE CORONARY ARTERIES NEC 4.2 
K4130B1A OPCS 4 TMR & CABG AUTOGRAFT REPLACEMENT OF THREE CORONARY ARTERIES NEC 4.2 
K4130B21 OPCS 4 AUTO REPLACE THREE CON ART AUTOGRAFT REPLACEMENT OF THREE CORONARY ARTERIES NEC 4.2 
K4130B22 OPCS 4 CABG + AVR + Carotid Endartere AUTOGRAFT REPLACEMENT OF THREE CORONARY ARTERIES NEC 4.2 
K414 OPCS 4 Autograft replacement of four  Autograft replacement of four or more coronary arteries NEC 4.2 
K4140 OPCS 4 CABG + AVR + Carotid Endartere 
AUTOGRAFT REPLACEMENT OF FOUR OR MORE CORONARY 
ARTERIES NEC 4.2 
K4140B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS  
AUTOGRAFT REPLACEMENT OF FOUR OR MORE CORONARY 
ARTERIES NEC 4.2 
K4140B11 OPCS 4 Coronary Artery Bypass Grafts 
AUTOGRAFT REPLACEMENT OF FOUR OR MORE CORONARY 
ARTERIES NEC 4.2 
K4140B1A OPCS 4 TMR & CABG 
AUTOGRAFT REPLACEMENT OF FOUR OR MORE CORONARY 
ARTERIES NEC 4.2 
K4140B21 OPCS 4 AUTO REPLACE FOUR > CON ART 
AUTOGRAFT REPLACEMENT OF FOUR OR MORE CORONARY 
ARTERIES NEC 4.2 
K4140B22 OPCS 4 CABG + AVR + Carotid Endartere 
AUTOGRAFT REPLACEMENT OF FOUR OR MORE CORONARY 
ARTERIES NEC 4.2 
K418 OPCS 4 Other specified other autograf Other specified other autograft replacement of coronary arte 4.2 
K4180 OPCS 4 TMR & CABG OTHER SPECIFIED 4.2 
K4180B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS OTHER AUTOGRAFT REPLACEMENT OF CORONARY ARTERY OS 4.2 
K4180B11 OPCS 4 CORONARY ARTERY BYPASS GRAFTS OTHER AUTOGRAFT REPLACEMENT OF CORONARY ARTERY OS 4.2 
K4180B1A OPCS 4 TMR & CABG OTHER AUTOGRAFT REPLACEMENT OF CORONARY ARTERY OS 4.2 
K419 OPCS 4 Unspecified other autograft re Unspecified other autograft replacement of coronary artery 4.2 
K4190 OPCS 4 TMR & CABG UNSPECIFIED 4.2 
K4190B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS 
OTHER AUTOGRAFT REPLACEMENT OF CORONARY ARTERY 
UNSPECIFIED 4.2 
K4190B11 OPCS 4 CORONARY ARTERY BYPASS GRAFTS 
OTHER AUTOGRAFT REPLACEMENT OF CORONARY ARTERY 
UNSPECIFIED 4.2 
K4190B1A OPCS 4 TMR & CABG 
OTHER AUTOGRAFT REPLACEMENT OF CORONARY ARTERY 
UNSPECIFIED 4.2 
K42 OPCS 4 
ALLOGRAFT REPLACEMENT OF 
CORON ALLOGRAFT REPLACEMENT OF CORONARY ARTERY 4.2 
K421 OPCS 4 Allograft replacement of one c Allograft replacement of one coronary artery 4.2 
K422 OPCS 4 Allograft replacement of two c Allograft replacement of two coronary arteries 4.2 
K423 OPCS 4 Allograft replacement of three Allograft replacement of three coronary arteries 4.2 
K424 OPCS 4 Allograft replacement of four  Allograft replacement of four or more coronary arteries 4.2 
K428 OPCS 4 Other specified allograft repl Other specified allograft replacement of coronary artery 4.2 
K429 OPCS 4 Unspecified allograft replacem Unspecified allograft replacement of coronary artery 4.2 
K43 OPCS 4 
PROSTHETIC REPLACEMENT OF 
CORO PROSTHETIC REPLACEMENT OF CORONARY ARTERY 4.2 
K431 OPCS 4 Prosthetic replacement of one  Prosthetic replacement of one coronary artery 4.2 
K432 OPCS 4 Prosthetic replacement of two  Prosthetic replacement of two coronary arteries 4.2 
K433 OPCS 4 Prosthetic replacement of thre Prosthetic replacement of three coronary arteries 4.2 
K434 OPCS 4 Prosthetic replacement of four Prosthetic replacement of four or more coronary arteries 4.2 
K438 OPCS 4 Other specified prosthetic rep Other specified prosthetic replacement of coronary artery 4.2 
K439 OPCS 4 Unspecified prosthetic replace Unspecified prosthetic replacement of coronary artery 4.2 
K44 OPCS 4 
OTHER REPLACEMENT OF 
CORONARY  OTHER REPLACEMENT OF CORONARY ARTERY 4.2 
K441 OPCS 4 Replacement of coronary arteri Replacement of coronary arteries using multiple methods 4.2 
K442 OPCS 4 Revision of replacement of cor Revision of replacement of coronary artery 4.2 
K4420 OPCS 4 POST OP ATTENTION TO GRAFTS -  REVISION OF REPLACEMENT OF CORONARY ARTERY 4.2 
K4420B15 OPCS 4 POST OP ATTENTION TO GRAFTS -  REVISION OF REPLACEMENT OF CORONARY ARTERY 4.2 
K448 OPCS 4 Other specified other replacem Other specified other replacement of coronary artery 4.2 
K449 OPCS 4 Unspecified other replacement  Unspecified other replacement of coronary artery 4.2 
K451 OPCS 4 Double anastomosis of mammary  Double anastomosis of mammary arteries to coronary arteries 4.2 
K4510B10 OPCS 4 
DOUBLE ANASTOMOSIS OF 
MAMMARY 
DOUBLE ANASTOMOSIS OF MAMMARY ARTERIES TO CORONARY 
ARTERIES 4.2 
K4510B11 OPCS 4 
DOUBLE ANASTOMOSIS OF 
MAMMARY 
DOUBLE ANASTOMOSIS OF MAMMARY ARTERIES TO CORONARY 
ARTERIES 4.2 
K4510B21 OPCS 4 CABG WITH VALVE REPAIR 
DOUBLE ANASTOMOSIS OF MAMMARY ARTERIES TO CORONARY 
ARTERIES 4.2 
K452 OPCS 4 Double anastomosis of thoracic Double anastomosis of thoracic arteries to coronary arteries 4.2 
K453 OPCS 4 Anastomosis of mammary artery  Anastomosis of mammary artery to left anterior descending co 4.2 
K4530 OPCS 4 Coronary Artery Bypass Grafts 
ANASTOMOSIS OF MAMMARY ARTERY TO LEFT ANTERIOR 
DESCENDING CO 4.2 
K4530B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B11 OPCS 4 CORONARY ARTERY BYPASS GRAFTS 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B13 OPCS 4 MIDCAB-MIN INVASIVE BYPASS GRA 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B14 OPCS 4 CORONARY BYPASS GRAFTS - ENDO 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B16 OPCS 4 REPAIR ASC. AORTA & COR. BYPAS 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B18 OPCS 4 CABG & OTHER MAJOR CARDIAC (EG 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B1A OPCS 4 TMR & CABG 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B1B OPCS 4 
CABG & CAROTID 
ENDARTERECTOMY 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B21 OPCS 4 REPLACEMENT/REPAIR OF VALVE(S) 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B22 OPCS 4 CABG + AVR + CAROTID ENDARTERE 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B23 OPCS 4 COMPOSITE REPL AORTA,VALVE + C 
ANAST MAMMARY ARTERY TO LT ANTERIOR DESCENDING CORON 
ARTERY 4.2 
K4530B62 OPCS 4 Coronary Artery Bypass Grafts 
ANASTOMOSIS OF MAMMARY ARTERY TO LEFT ANTERIOR 
DESCENDING CO 4.2 
K454 OPCS 4 Anastomosis of mammary artery  Anastomosis of mammary artery to coronary artery NEC 4.2 
K4540 OPCS 4 Coronary Artery Bypass Grafts ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B10 OPCS 4 CORONARY ARTERY BYPASS GRAFTS  ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B11 OPCS 4 Coronary Artery Bypass Grafts ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B12 OPCS 4 Coronary Artery Bypass Grafts ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B14 OPCS 4 CORONARY BYPASS GRAFTS - ENDO  ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B16 OPCS 4 REPAIR ASC. AORTA & COR. BYPAS ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B18 OPCS 4 CABG & OTHER MAJOR CARDIAC (EG ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B1A OPCS 4 TMR & CABG ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B1B OPCS 4 
CABG & CAROTID 
ENDARTERECTOMY ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B21 OPCS 4 REPLACE/REPAIR VALVE(S) & CABG ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B22 OPCS 4 CABG + AVR + Carotid Endartere ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K4540B23 OPCS 4 COMPOSITE REPL AORTA,VALVE + C ANASTOMOSIS OF MAMMARY ARTERY TO CORONARY ARTERY NEC 4.2 
K455 OPCS 4 Anastomosis of thoracic artery Anastomosis of thoracic artery to coronary artery NEC 4.2 
K456 OPCS 4 Revision of connection of thor Revision of connection of thoracic artery to coronary artery 4.2 
K458 OPCS 4 Other specified connection of  Other specified connection of thoracic artery to coronary ar 4.2 
K459 OPCS 4 Unspecified connection of thor Unspecified connection of thoracic artery to coronary artery 4.2 
K46 OPCS 4 OTHER BYPASS OF CORONARY ARTER OTHER BYPASS OF CORONARY ARTERY 4.2 
K463 OPCS 4 Implantation of mammary artery Implantation of mammary artery into heart NEC 4.2 
K468 OPCS 4 Other specified other bypass o Other specified other bypass of coronary artery 4.2 
K469 OPCS 4 Unspecified other bypass of co Unspecified other bypass of coronary artery 4.2 
K49 OPCS 4 
TRANSLUMINAL BALLOON 
ANGIOPLAS TRANSLUMINAL BALLOON ANGIOPLASTY OF CORONARY ARTERY 4.2 
K491 OPCS 4 Percutaneous transluminal ball Percutaneous transluminal balloon angioplasty of one coronar 4.2 
K4910 OPCS 4 LASER ANGIOPLASTY - ONE BALLOO 
PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY OF ONE 
CORONAR 4.2 
K4910D11 OPCS 4 ABANDONED PTCA 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D12 OPCS 4 SIMPLE PTCA - ONE OR TWO BALLO 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D21 OPCS 4 SIMPLE PTCA-MORE THAN 2 BALLOO 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D34 OPCS 4 PTCA - ONE STENT & ONE BALLOON 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D35 OPCS 4 PTCA - 1 STENT, NO BALLOON 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D37 OPCS 4 LASER ANGIOPLASTY - ONE BALLOO 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D41 OPCS 4 PTCA - 2 OR MORE STENTS 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D42 OPCS 4 PTCA - 2 OR MORE STENTS, NO BA 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D44 OPCS 4 PTCA WITH STENT & ROTABLATOR 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D45 OPCS 4 PTCA WITH STENT - 2+ BALLOONS 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D49 OPCS 4 PTCA WITH 2+STENTS (2+ BALLOON 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D4B OPCS 4 LASER ANGIOPLASTY, MORE THAN O 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K4910D4C OPCS 4 LASER ANGIOPLASTY WITH STENT(S 
PERCUT TRANSLUMINAL BALLOON ANGIOPLASTY ONE CORONARY 
ARTERY 4.2 
K492 OPCS 4 Percutaneous transluminal ball Percutaneous transluminal balloon angioplasty of multiple co 4.2 
K4920 OPCS 4 PTCA with Stent & Rotablator 
PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY OF 
MULTIPLE CO 4.2 
K4920D11 OPCS 4 ABANDONED PTCA 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D12 OPCS 4 SIMPLE PTCA - ONE OR TWO BALLO 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D21 OPCS 4 SIMPLE PTCA-MORE THAN 2 BALLOO 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D34 OPCS 4 PTCA - ONE STENT & ONE BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D35 OPCS 4 PTCA - 1 STENT, NO BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D37 OPCS 4 LASER ANGIOPLASTY - 1 BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D41 OPCS 4 PTCA - 2 OR MORE STENTS 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D42 OPCS 4 PTCA - 2 STENTS, NO BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D44 OPCS 4 PTCA WITH STENT & ROTABLATOR 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D45 OPCS 4 PTCA WITH STENT - 2+ BALLOONS 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D49 OPCS 4 PTCA WITH 2+STENTS (2+ BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D4B OPCS 4 LASER ANGIOPLASTY - 1 BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K4920D4C OPCS 4 LASER ANGIOPLASTY WITH STENT(S 
PERCUT TRANSLUM BALLOON ANGIOPLASTY MULITPLE CORON 
ARTERIES 4.2 
K493 OPCS 4 Percutaneous transluminal ball Percutaneous transluminal balloon angioplasty of bypass graf 4.2 
K4930 OPCS 4 PTCA with Stent & Rotablator 
PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY OF BYPASS 
GRAF 4.2 
K4930D12 OPCS 4 SIMPLE PTCA - ONE OR TWO BALLO 
PERCUT TRANSLUM BALLOON ANGIOPLASTY BYPASS GRAFT CORON 
ART 4.2 
K4930D21 OPCS 4 SIMPLE PTCA-MORE THAN 2 BALLOO 
PERCUT TRANSLUM BALLOON ANGIOPLASTY BYPASS GRAFT CORON 
ART 4.2 
K4930D34 OPCS 4 PTCA - ONE STENT & ONE BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY BYPASS GRAFT CORON 
ART 4.2 
K4930D35 OPCS 4 PTCA - 1 STENT, NO BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY BYPASS GRAFT CORON 
ART 4.2 
K4930D41 OPCS 4 PTCA - 2 OR MORE STENTS 
PERCUT TRANSLUM BALLOON ANGIOPLASTY BYPASS GRAFT CORON 
ART 4.2 
K4930D44 OPCS 4 PTCA WITH STENT & ROTABLATOR 
PERCUT TRANSLUM BALLOON ANGIOPLASTY BYPASS GRAFT CORON 
ART 4.2 
K4930D45 OPCS 4 PTCA WITH STENT - 2+ BALLOONS 
PERCUT TRANSLUM BALLOON ANGIOPLASTY BYPASS GRAFT CORON 
ART 4.2 
K4930D49 OPCS 4 PTCA WITH 2+STENTS (2+ BALLOON 
PERCUT TRANSLUM BALLOON ANGIOPLASTY BYPASS GRAFT CORON 
ART 4.2 
K494 OPCS 4 Percutaneous transluminal cutt Percutaneous transluminal cutting balloon angioplasty of cor 4.2 
K498 OPCS 4 Other specified transluminal b Other specified transluminal balloon angioplasty of coronary 4.2 
K4980 OPCS 4 PTCA with Stent & Rotablator OTHER SPECIFIED 4.2 
K4980D34 OPCS 4 PTCA - ONE STENT & ONE BALLOON TRANSLUMINAL BALLOON ANGIOPLASTY OF CORONARY ARTERY OS 4.2 
K4980D41 OPCS 4 PTCA - 2 OR MORE STENTS TRANSLUMINAL BALLOON ANGIOPLASTY OF CORONARY ARTERY OS 4.2 
K4980D44 OPCS 4 PTCA WITH STENT & ROTABLATOR TRANSLUMINAL BALLOON ANGIOPLASTY OF CORONARY ARTERY OS 4.2 
K4980D45 OPCS 4 PTCA WITH STENT - 2+ BALLOONS TRANSLUMINAL BALLOON ANGIOPLASTY OF CORONARY ARTERY OS 4.2 
K4980D49 OPCS 4 PTCA WITH 2+STENTS (2+ BALLOON TRANSLUMINAL BALLOON ANGIOPLASTY OF CORONARY ARTERY OS 4.2 
K499 OPCS 4 Unspecified transluminal ballo Unspecified transluminal balloon angioplasty of coronary art 4.2 
K50 OPCS 4 
OTHER THERAPEUTIC 
TRANSLUMINAL 
OTHER THERAPEUTIC TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY 4.2 
K501 OPCS 4 Percutaneous transluminal lase Percutaneous transluminal laser coronary angioplasty 4.2 
K5010 OPCS 4 LASER ANGIOPLASTY - NO BALLOON PERCUTANEOUS TRANSLUMINAL LASER CORONARY ANGIOPLASTY 4.2 
K5010D36 OPCS 4 LASER ANGIOPLASTY - NO BALLOON PERCUTANEOUS TRANSLUMINAL LASER CORONARY ANGIOPLASTY 4.2 
K502 OPCS 4 Percutaneous transluminal coro Percutaneous transluminal coronary thrombolysis using strept 4.2 
K503 OPCS 4 Percutaneous transluminal inje Percutaneous transluminal injection of therapeutic substance 4.2 
K504 OPCS 4 Percutaneous transluminal athe Percutaneous transluminal atherectomy of coronary artery 4.2 
K508 OPCS 4 Other specified other therapeu Other specified other therapeutic transluminal operations on 4.2 
K5080 OPCS 4 PTCA with Rota -1 balloon,1 or PTDA 4.2 
K5080D31 OPCS 4 PTCA WITH ROTA -1 BALLOON,1 OR 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K5080D32 OPCS 4 CORONARY TEC - ONE BALLOON 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K5080D33 OPCS 4 DCA - ONE BALLOON 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K5080D43 OPCS 4 PTCA-2 OR MORE ROTABLATORS 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K5080D44 OPCS 4 PTCA WITH STENT & ROTABLATOR 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K5080D46 OPCS 4 PTCA WITH ROTABLATOR - 2+ BALL 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K5080D47 OPCS 4 CORONARY TEC - 2+ BALLOONS 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K5080D48 OPCS 4 DCA - 2+BALLOONS 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K5080D4A OPCS 4 CORONARY TEC WITH STENT(S) INC 
OTHER THERAP TRANSLUMINAL OPERATIONS ON CORONARY 
ARTERY OS 4.2 
K509 OPCS 4 Unspecified other therapeutic  
Unspecified other therapeutic transluminal operations on coronary 
artery 4.2 
K75 OPCS 4 
PERCUTANEOUS TRANSLUMINAL 
BALL 
PERCUTANEOUS TRANSLUMINAL BALLOON ANGIOPLASTY AND 
STENTING O 4.2 
K751 OPCS 4 Percutaneous transluminal ball Percutaneous transluminal balloon angioplasty and insertion  4.2 
K752 OPCS 4 Percutaneous transluminal ball Percutaneous transluminal balloon angioplasty and insertion  4.2 
K753 OPCS 4 Percutaneous transluminal ball Percutaneous transluminal balloon angioplasty and insertion  4.2 
K754 OPCS 4 Percutaneous transluminal ball Percutaneous transluminal balloon angioplasty and insertion  4.2 
K758 OPCS 4 Other specified percutaneous t Other specified percutaneous transluminal balloon angioplasty 4.2 
K759 OPCS 4 Unspecified percutaneous trans Unspecified percutaneous transluminal balloon angioplasty an 4.2 
 
Table 2b: ICD 10 codes used to identify type 1 myocardial infarctions 
CLINICAL_CODE CODE_SET_ID VERSION SHORT_DESC 
LONG_DESC 
 
I20 ICD 10 Angina pectoris Angina pectoris 
I200 ICD 10   UNSTABLE ANGINA 
I201 ICD 10   ANGINA PECTORIS WITH DOCUMENTED SPASM 
I208 ICD 10   OTHER FORMS OF ANGINA PECTORIS 
I209 ICD 10   ANGINA PECTORIS, UNSPECIFIED 
I21 ICD 10 Acute myocardial infarction Acute myocardial infarction 
I210 ICD 10   ACUTE TRANSMURAL MYOCARDIAL INFARCTION OF ANTERIOR WALL 
I211 ICD 10   ACUTE TRANSMURAL MYOCARDIAL INFARCTION OF INFERIOR WALL 
I212 ICD 10   ACUTE TRANSMURAL MYOCARDIAL INFARCTION OF OTHER SITES 
I213 ICD 10   ACUTE TRANSMURAL MYOCARDIAL INFARCTION OF UNSPECIFIED SITE 
I214 ICD 10   ACUTE SUBENDOCARDIAL MYOCARDIAL INFARCTION 
I219 ICD 10   ACUTE MYOCARDIAL INFARCTION, UNSPECIFIED 
I22 ICD 10 
Subsequent myocardial 
infarction Subsequent myocardial infarction                              
I220 ICD 10   SUBSEQUENT MYOCARDIAL INFARCTION OF ANTERIOR WALL 
I221 ICD 10   SUBSEQUENT MYOCARDIAL INFARCTION OF INFERIOR WALL 
I228 ICD 10   SUBSEQUENT MYOCARDIAL INFARCTION OF OTHER SITES 
I229 ICD 10   SUBSEQUENT MYOCARDIAL INFARCTION OF UNSPECIFIED SITE 
I24 ICD 10 
Other acute ischaemic heart 
disease Other acute ischaemic heart disease                               
I240 ICD 10   CORONARY THROMBOSIS NOT RESULTING IN MYOCARDIAL INFARCTION 
I241 ICD 10   DRESSLER'S SYNDROME 
I248 ICD 10   OTHER FORMS OF ACUTE ISCHAEMIC HEART DISEASE 
I249 ICD 10   ACUTE ISCHAEMIC HEART DISEASE, UNSPECIFIED 
I25 ICD 10 Chronic ischaemic heart disease Chronic ischaemic heart disease                               
I250 ICD 10   ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, SO DESCRIBED 
I251 ICD 10   ATHEROSCLEROTIC HEART DISEASE 
I253 ICD 10   ANEURYSM OF HEART 
I254 ICD 10   CORONARY ARTERY ANEURYSM 
I255 ICD 10   ISCHAEMIC CARDIOMYOPATHY 
I256 ICD 10   SILENT MYOCARDIAL ISCHAEMIA 
I46 ICD 10 Cardiac arrest Cardiac arrest 
I460 ICD 10   CARDIAC ARREST WITH SUCCESSFUL RESUSCITATION 
I461 ICD 10   SUDDEN CARDIAC DEATH, SO DESCRIBED 
I469 ICD 10   CARDIAC ARREST, UNSPECIFIED 
R071 ICD 10   CHEST PAIN ON BREATHING 
R072 ICD 10   PRECORDIAL PAIN 
R073 ICD 10   OTHER CHEST PAIN 
R074 ICD 10   CHEST PAIN, UNSPECIFIED 
R96 ICD 10 Other sudden death, cause unkn Other sudden death, cause unkn                               
R960 ICD 10   INSTANTANEOUS DEATH 
R961 ICD 10   DEATH OCCURRING LESS THAN 24 HOURS FROM ONSET OF SYMPTOMS, N 
R98X ICD 10   UNATTENDED DEATH 
R99X ICD 10   OTHER ILL-DEFINED AND UNSPECIFIED CAUSES OF MORTALITY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 3 Re-presentation (up to 1 year following index discharge) to English hospitals with any ischaemic 
heart disease or coronary revascularisation code: troponin assays in use and reference ranges 
Hospital Assay Manufacturer High 
sensitive 
assay 
Reference 
range 
Units 
 
St Helens and 
Knowsley NHS trust 
Troponin I Siemens No ≤0.05 micrograms/l 
East Cheshire 
Hospital NHS trust 
TroponinI Beckman Yes <34 nanograms/l 
Southport hospital 
NHS Trust 
Troponin 
T 
Roche yes <15 nanograms/l 
Warrington Hospital 
NHS Trust 
Troponin I Siemens no <0.03 Micrograms/l 
University hospital 
Aintree NHS 
Foundation Trust 
Troponin 
T 
Roche yes <15 nanograms/l 
Royal Liverpool 
Hospitals  
Troponin 
T 
Roche yes <15 nanograms/l 
Liverpool Heart and 
Chest hospital NHS 
foundation trust 
Troponin 
T 
Roche yes <15 nanograms/l 
Pilgrim Hospital Troponin 
T 
Roche Yes <15 (female) 
<10 (male) 
nanograms/l 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 4 Inter-observer variability in risk score determination 
 
*agreement of risk category determination (low, intermediate, high risk score determination of each 
risk score) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk SCORE 
Inter-observer variability in determination of risk scores 
Absolute Risk category* 
Agreement Agreement κ 
HEART 16/18 (89%) 18/18 (100%) 1.0 
TIMI 13/18 (72%) 18/18 (100%) 1.0 
GRACE 11/18 (61%) 17/18 (94%) 0.82 
 Table 5 Interaction of timing of high sensitivity troponin T check relative to 
CP onset and outcome (MACE) 
Rule-Out Protocol Chest pain (peak) to first troponin Check (hours) (n-discharged, npv with 
confidence intervals at 42 days) 
 <3 ≥3 P 
value 
<6 ≥6 P value 
HStnT <15 and nonischaemic ECG 40 (0.976 
(0.871 – 
0.999)) 
913 (0.983 
(0.972-
0.990)) 
0.563 128 (0.985 
(0.946-
0.998)) 
825 (0.982 
(0.971-
0.990)) 
1.000 
HsTnt <5 and nonischaemic ECG 23 (1.000 
(0.852 – 
1.000)) 
579 (0.998 
(0.990 – 
1.000) 
1.000 71 (1.000 
(0.949-
1.000)) 
531 (0.998 
(0.990-
1.000)) 
1.000 
HEART ≤3 36 (1.000 
(0.903-1.000)) 
831 (0.994 
(0.986-
0.998) 
1.000 101 (0.990 
(0.947-
1.000)) 
766 (0.995 
(0.987-
0.999)) 
0.464 
TIMI≤1 40 (0.976 
(0.871-0.999)) 
867 (0.980 
(0.968-
0.988)) 
0.581 116 (0.959 
(0.906-
0.986)) 
791 (0.983 
(0.971-
0.990)) 
0.090 
GRACE ≤75 25 (0.962 
(0.804 – 
0.999)) 
433 (0.982 
(0.965-
0.992)) 
0.406 65 (0.970 
(0.896-
0.996)) 
393 (0.983 
(0.964-
0.993)) 
0.623 
Abbreviations: NPV= negative predictive value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1: Negative and Positive predictive values for MACE (type 1 myocardial infarction, 
unplanned coronary revascularisation and all cause death) at 6 weeks according to rule-
out strategies (dashed lines represents 99% NPV)  
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: Time of chest pain to first High sensitivity troponin T sampling 
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